Shane Kovacs
2017 - PTC Therapeutics
In 2017, Shane Kovacs earned a total compensation of $707.7K as Former Executive Vice President, Chief Financial Officer and Head of Corporate Development at PTC Therapeutics, a 67% decrease compared to previous year.
Compensation breakdown
Option Awards | $406,010 |
---|---|
Salary | $189,436 |
Stock Awards | $101,070 |
Other | $11,206 |
Total | $707,722 |
Kovacs received $406K in option awards, accounting for 57% of the total pay in 2017.
Kovacs also received $189.4K in salary, $101.1K in stock awards and $11.2K in other compensation.
Rankings
In 2017, Shane Kovacs' compensation ranked 10,565th out of 14,666 executives tracked by ExecPay. In other words, Kovacs earned more than 28.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 10,565 out of 14,666 | 28th |
Division Manufacturing | 4,109 out of 5,772 | 29th |
Major group Chemicals And Allied Products | 1,464 out of 2,075 | 29th |
Industry group Drugs | 1,195 out of 1,731 | 31st |
Industry Pharmaceutical Preparations | 929 out of 1,333 | 30th |
Source: SEC filing on April 30, 2018.
Kovacs' colleagues
We found six more compensation records of executives who worked with Shane Kovacs at PTC Therapeutics in 2017.
2017
Stuart Peltz
PTC Therapeutics
Chief Executive Officer
2017
Marcio Souza
PTC Therapeutics
Chief Operating Officer
2017
Mark Boulding
PTC Therapeutics
Chief Legal Officer
2017
Mark Rothera
PTC Therapeutics
Former Chief Commercial Officer
2017
Neil Almstead
PTC Therapeutics
Executive Vice President, Research, Pharmaceutical Operations & Technology
2017
Christine Utter
PTC Therapeutics